These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36333972)

  • 21. Escalation strategies for combination therapy Phase I trials.
    Sweeting MJ; Mander AP
    Pharm Stat; 2012; 11(3):258-66. PubMed ID: 22411472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bayesian adaptive designs in single ascending dose trials in healthy volunteers.
    Guédé D; Reigner B; Vandenhende F; Derks M; Beyer U; Jordan P; Worth E; Diack C; Frey N; Peck R
    Br J Clin Pharmacol; 2014 Aug; 78(2):393-400. PubMed ID: 24528176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials.
    Shi H; Cao J; Yuan Y; Lin R
    Stat Med; 2021 May; 40(11):2626-2649. PubMed ID: 33650708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN).
    Zhao Y; Yuan Y; Korn EL; Freidlin B
    Clin Cancer Res; 2024 Feb; 30(4):673-679. PubMed ID: 38048044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designing phase I oncology dose escalation using dose-exposure-toxicity models as a complementary approach to model-based dose-toxicity models.
    Pantoja K; Lanke S; Munafo A; Victor A; Habermehl C; Schueler A; Venkatakrishnan K; Girard P; Goteti K
    CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1371-1381. PubMed ID: 35852048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bayesian adaptive dose-escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacy.
    Yeung WY; Reigner B; Beyer U; Diack C; Sabanés Bové D; Palermo G; Jaki T
    Pharm Stat; 2017 Nov; 16(6):396-413. PubMed ID: 28691311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
    Chen Z; Tighiouart M; Kowalski J
    Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
    Koopmeiners JS; Modiano J
    Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incorporating historical information to improve phase I clinical trials.
    Zhou Y; Lee JJ; Wang S; Bailey S; Yuan Y
    Pharm Stat; 2021 Nov; 20(6):1017-1034. PubMed ID: 33793044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades.
    Takeda K; Xia Q; Liu S; Rong A
    Pharm Stat; 2022 Mar; 21(2):496-506. PubMed ID: 34862715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials.
    Dinart D; Fraisse J; Tosi D; Mauguen A; Touraine C; Gourgou S; Le Deley MC; Bellera C; Mollevi C
    BMC Med Inform Decis Mak; 2020 Jun; 20(1):134. PubMed ID: 32580715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design.
    Zhu J; Sabanés Bové D; Liao Z; Beyer U; Yung G; Sarkar S
    Contemp Clin Trials; 2021 Aug; 107():106436. PubMed ID: 34000410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multi-stage dose expansion cohort (MSDEC) design with Bayesian stopping rule.
    Wang S; Tan M
    J Biopharm Stat; 2022 Jul; 32(4):600-612. PubMed ID: 35699319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal dose escalation methods using deep reinforcement learning in phase I oncology trials.
    Matsuura K; Sakamaki K; Honda J; Sozu T
    J Biopharm Stat; 2023 Sep; 33(5):639-652. PubMed ID: 36717962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accuracy, Safety, and Reliability of Novel Phase I Trial Designs.
    Zhou H; Yuan Y; Nie L
    Clin Cancer Res; 2018 Sep; 24(18):4357-4364. PubMed ID: 29661774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
    Tighiouart M; Li Q; Rogatko A
    Stat Med; 2017 Jan; 36(2):280-290. PubMed ID: 27060889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between continuous and discrete doses for model based designs in cancer dose finding.
    Diniz MA; Tighiouart M; Rogatko A
    PLoS One; 2019; 14(1):e0210139. PubMed ID: 30625194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A hybrid design for dose-finding oncology clinical trials.
    Liao JJZ; Zhou F; Zhou H; Petruzzelli L; Hou K; Asatiani E
    Int J Cancer; 2022 Nov; 151(9):1602-1610. PubMed ID: 35802470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trials.
    Mu R; Xu G; Liu G; Pan H
    Contemp Clin Trials; 2021 Sep; 108():106504. PubMed ID: 34303862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS).
    Pan H; Xie F; Liu P; Xia J; Ji Y
    Clin Trials; 2014 Feb; 11(1):49-59. PubMed ID: 24137041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.